- Home
- QCRH vs INVA Comparison
QCRH vs INVA Comparison
Compare QCRH & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | INVA |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | QCRH | INVA |
|---|---|---|
| Price | $95.29 | $22.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $98.25 | $32.80 |
| AVG Volume (30 Days) | 84.2K | ★ 732.6K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | 11.62 | ★ 816.67 |
| EPS | 1.99 | ★ 2.22 |
| Revenue | $165,999,610.00 | ★ $217,217,000.00 |
| Revenue This Year | $8.46 | $8.95 |
| Revenue Next Year | $5.59 | $12.65 |
| P/E Ratio | $47.34 | ★ $10.18 |
| Revenue Growth | 20.72 | ★ 62.63 |
| 52 Week Low | $64.23 | $16.52 |
| 52 Week High | $97.25 | $25.15 |
Technical Indicators
Market Signals| Indicator | QCRH | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 49.51 |
| Support Level | $86.16 | $22.20 |
| Resistance Level | N/A | $23.03 |
| Average True Range (ATR) | 2.27 | 0.55 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 76.04 | 54.64 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.